Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Rapport Therapeutics Inc....

    NASDAQ: RAPP · Real-Time Price · USD
    11.00
    -0.20 (-1.79%)
    At close: Jun 17, 2025, 3:59 PM
    11.49
    4.45%
    After-hours: Jun 17, 2025, 06:04 PM EDT

    Rapport Therapeutics Common Stock Statistics

    Share Statistics

    Rapport Therapeutics Common Stock has 36.5M shares outstanding. The number of shares has increased by 3.17% in one year.

    Shares Outstanding

    n/a
    		 36.5M

    Shares Change (YoY)

    n/a
    		 3.17%

    Shares Change (QoQ)

    n/a
    		 -0.22%

    Owned by Institutions (%)

    n/a
    		 99.99%

    Shares Floating

    n/a
    		 17.4M

    Failed to Deliver (FTD) Shares

    n/a
    		 2,896

    FTD / Avg. Volume

    n/a
    		 1.38%

    Short Selling Information

    The latest short interest is 2.62M, so 7.19% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 2.62M

    Short % of Shares Out

    n/a
    		 7.19%

    Short % of Float

    n/a
    		 17.45%

    Short Ratio (days to cover)

    n/a
    		 12.96

    Valuation Ratios

    The PE ratio is -46.98 and the forward PE ratio is -2.59. Rapport Therapeutics Common Stock's PEG ratio is -0.47.

    PE Ratio

    n/a
    		 -46.98

    Forward PE

    n/a
    		 -2.59

    PS Ratio

    n/a
    		 0

    Forward PS

    n/a
    		 16.3

    PB Ratio

    n/a
    		 12.05

    P/FCF Ratio

    n/a
    		 -54.72

    PEG Ratio

    n/a
    		 -0.47
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Rapport Therapeutics Common Stock.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 35.34, with a Debt / Equity ratio of 0.

    Current Ratio

    n/a
    		 35.34

    Quick Ratio

    n/a
    		 35.34

    Debt / Equity

    n/a
    		 0

    Debt / EBITDA

    n/a
    		 -0.02

    Debt / FCF

    n/a
    		 -0.02

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 n/a

    Profits Per Employee

    n/a
    		 $-1,134,884.06

    Employee Count

    n/a
    		 69

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by -56.49% in the last 52 weeks. The beta is -0.88, so Rapport Therapeutics Common Stock's price volatility has been lower than the market average.

    Beta

    n/a
    		 -0.88

    52-Week Price Change

    n/a
    		 -56.49%

    50-Day Moving Average

    n/a
    		 10.59

    200-Day Moving Average

    n/a
    		 16.04

    Relative Strength Index (RSI)

    n/a
    		 49.12

    Average Volume (20 Days)

    n/a
    		 210,242

    Income Statement

    Revenue

    n/a
    		 n/a

    Gross Profit

    n/a
    		 n/a

    Operating Income

    n/a
    		 -83.06M

    Net Income

    n/a
    		 -78.31M

    EBITDA

    n/a
    		 -77.47M

    EBIT

    n/a
    		 -78.31M

    Earnings Per Share (EPS)

    n/a
    		 -0.38
    Full Income Statement

    Balance Sheet

    The company has 56.8M in cash and 1.48M in debt, giving a net cash position of 55.33M.

    Cash & Cash Equivalents

    n/a
    		 56.8M

    Total Debt

    n/a
    		 1.48M

    Net Cash

    n/a
    		 55.33M

    Retained Earnings

    n/a
    		 -123.75M

    Total Assets

    n/a
    		 302.05M

    Working Capital

    n/a
    		 281.58M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -64.83M and capital expenditures -2.4M, giving a free cash flow of -67.23M.

    Operating Cash Flow

    n/a
    		 -64.83M

    Capital Expenditures

    n/a
    		 -2.4M

    Free Cash Flow

    n/a
    		 -67.23M

    FCF Per Share

    n/a
    		 -0.32
    Full Cash Flow Statement

    Margins

    Gross Margin

    n/a
    		 n/a

    Operating Margin

    n/a
    		 n/a

    Pretax Margin

    n/a
    		 n/a

    Profit Margin

    n/a
    		 n/a

    EBITDA Margin

    n/a
    		 n/a

    EBIT Margin

    n/a
    		 n/a

    FCF Margin

    n/a
    		 n/a

    Dividends & Yields

    RAPP does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for RAPP is $35, which is 218.2% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $35

    Price Target Difference

    n/a
    		 218.2%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 5
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 10.91

    Piotroski F-Score

    n/a
    		 2

    Add to Watchlist